SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0000950170-24-044774
Filing Date
2024-04-16
Accepted
2024-04-16 16:10:22
Documents
18
Period of Report
2024-06-12

Document Format Files

Seq Description Document Type Size
1 PRE 14A ntla-20240416.htm   iXBRL PRE 14A 1799373
2 GRAPHIC img109974523_0.jpg GRAPHIC 28853
3 GRAPHIC img109974523_1.jpg GRAPHIC 28853
4 GRAPHIC img109974523_2.jpg GRAPHIC 26473
5 GRAPHIC img109974523_3.jpg GRAPHIC 40294
6 GRAPHIC img109974523_4.jpg GRAPHIC 500810
7 GRAPHIC img109974523_5.jpg GRAPHIC 194892
  Complete submission text file 0000950170-24-044774.txt   4338660

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ntla-20240416.xsd EX-101.SCH 26462
21 EXTRACTED XBRL INSTANCE DOCUMENT ntla-20240416_htm.xml XML 143063
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-37766 | Film No.: 24847916
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)